SCHEMBL6720664

SCHEMBL6720664

COc1cnc2c(c1)C(O)=C(C(=O)O)N(C)S2(=O)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.35
PTGS1 P23219 2/20 0.35
PTGS2 P35354 2/20 0.35
USP2 O75604 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
ALOX15 P16050 1/20 0.35
NFKB1 P19838 1/20 0.35
BLM P54132 1/20 0.35
SLC22A6 Q4U2R8 1/20 0.35
SLC22A8 Q8TCC7 1/20 0.35
ABCB11 O95342 1/20 0.35
GLA P06280 1/20 0.35
EDNRA P25101 1/20 0.35
MAPK1 P28482 2/20 0.34
LMNA P02545 1/20 0.33
KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6720534 0.76 CYP1A2 (0.51) KDM4EPTGS1PTGS2USP2CYP1A2
SCHEMBL6720680 0.76 PTGS1 (0.39) KDM4EPTGS1PTGS2USP2CYP1A2
SCHEMBL6720612 0.73 PTGES (0.41) KDM4EPTGS2MAPK1ALDH1A1GAA
SCHEMBL6720681 0.71 BRS3 (0.37) KDM4EPTGS1PTGS2USP2CYP1A2
SCHEMBL10958273 0.65 CYP1A2 (0.50) KDM4EPTGS1PTGS2USP2CYP1A2
SCHEMBL11487932 0.64 PTGS1 (0.72) KDM4EPTGS1PTGS2USP2CYP1A2
SCHEMBL2351157 0.63 HSD11B1 (0.66) KDM4EPTGS1PTGS2USP2CYP1A2
SCHEMBL31032837 0.62 SMN1; SMN2 (0.45) KDM4ECYP1A2MAPK1LMNAALDH1A1
SCHEMBL1241243 0.62 MAPT (0.43) KDM4EPTGS2USP2CYP1A2CYP2C19
SCHEMBL21332013 0.60 MAPT (0.42) KDM4EBLMGLALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183236-B2 Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2012-05-22 US disclosed
US-8183236-B2 Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2012-05-22 US disclosed
US-20090088420-A1 COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-04-02 US disclosed
US-20090088420-A1 COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088420-A1 COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS TYMP, IMPDH1, SAMHD1 KDM4E 1795/4885PTGS1 1768/4885PTGS2 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.